Description
Description: Epithra 50 mg Injection is a potent chemotherapy medication manufactured by Glenmark (Onkos) Pharmaceuticals Ltd. Each vial contains 50 milligrams (mg) of the active ingredient Epirubicin. This medication is a member of the anthracycline class of drugs and is widely used in the treatment of various types of cancer.
Active Ingredient: The active ingredient in Epithra is Epirubicin. Epirubicin is a cytotoxic anthracycline antibiotic that works by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation. It is effective against a wide range of cancers, including breast cancer, ovarian cancer, and certain types of leukemia.
Manufacturer: Epithra 50 mg Injection is manufactured by Glenmark (Onkos) Pharmaceuticals Ltd., a reputable pharmaceutical company known for its commitment to producing high-quality medications. Glenmark (Onkos) Pharmaceuticals Ltd. adheres to stringent quality standards to ensure the safety and efficacy of its products.
Uses: Epithra 50 mg Injection is indicated for the treatment of various types of cancer, including breast cancer, ovarian cancer, and soft tissue sarcomas. It may be used alone or in combination with other chemotherapy drugs or radiation therapy, depending on the specific type and stage of cancer being treated.
How to Use: Epithra 50 mg Injection is administered intravenously (into a vein) by a qualified healthcare professional, such as a doctor or nurse, in a clinical setting. The dosage and frequency of administration will vary depending on factors such as the patient’s weight, overall health, and the type of cancer being treated. It is essential to follow the healthcare provider’s instructions carefully.
Storage Conditions: Epithra 50 mg Injection should be stored according to the manufacturer’s instructions, typically at room temperature away from heat, light, and moisture. The vials should be kept in their original packaging and protected from freezing. It is essential to keep the medication out of reach of children and pets.
Precautions:
- Epithra 50 mg Injection should be used with caution in patients with pre-existing heart conditions, liver or kidney impairment, or a history of bone marrow suppression.
- Patients receiving Epithra should undergo regular blood tests to monitor for potential side effects, such as bone marrow suppression and cardiotoxicity.
- It is essential to inform the healthcare provider about any medications, supplements, or herbal products being taken before starting treatment with Epithra.
Contraindications: Epithra 50 mg Injection is contraindicated in patients with a known hypersensitivity to Epirubicin or any of the components in the formulation. It should not be used in patients with severe liver or kidney dysfunction or in pregnant or breastfeeding women.
Side Effects: Common side effects associated with Epithra 50 mg Injection may include nausea, vomiting, hair loss, fatigue, and decreased blood cell counts (anemia, leukopenia, thrombocytopenia). More severe side effects, such as cardiotoxicity and allergic reactions, are possible but less common. Promptly report any unusual or severe symptoms to a healthcare provider.
Reviews
There are no reviews yet.